MBX Biosciences (MBX) Change in Accured Expenses (2023 - 2026)

MBX Biosciences has reported Change in Accured Expenses for 4 years, with the latest figure at -$4.9 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 970.43% year-over-year to -$4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 66.64% YoY) and the FY2025 annual result came in at $6.8 million, up 114.32% from the prior year.
• Change in Accured Expenses eased to -$4.9 million in Q1 2026 per MBX's latest filing, from $4.5 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.5 million in Q4 2025 and troughed at -$4.9 million in Q1 2026.
• A 4-year average of $392900.0 and a median of $177500.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses jumped 2293.6% in 2025, then tumbled 970.43% in 2026.
• Over 4 years, Change in Accured Expenses stood at -$1.2 million in 2023, then surged by 82.81% to -$203000.0 in 2024, then surged by 2293.6% to $4.5 million in 2025, then sank by 209.07% to -$4.9 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$4.9 million, $4.5 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.